<?xml version="1.0" ?>
<document id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c">
  <chunk id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c0" text="Genetic Vaccines and Therapy Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen">
    <entity charOffset="126-129" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c0.e0" ontology_id="CHEBI_16991" text="DNA" type="chemical"/>
    <entity charOffset="175-178" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c0.e1" ontology_id="CHEBI_16991" text="DNA" type="chemical"/>
    <entity charOffset="186-193" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c0.e2" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
  </chunk>
  <chunk id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1" text="Background: Hepatitis C core protein is an attractive target for HCV vaccine aimed to exterminate HCV infected cells. However, although highly immunogenic in natural infection, core appears to have low immunogenicity in experimental settings. We aimed to design an HCV vaccine prototype based on core, and devise immunization regimens that would lead to potent anti-core immune responses which circumvent the immunogenicity limitations earlier observed.">
    <entity charOffset="12-21" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e0" ontology_id="DOID_2237" text="Hepatitis" type="disease"/>
    <entity charOffset="12-23" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e1" ontology_id="DOID_1883" text="Hepatitis C" type="disease"/>
    <entity charOffset="24-36" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e2" ontology_id="CHEBI_81639" text="core protein" type="chemical"/>
    <entity charOffset="29-36" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e3" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <pair e1="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e0" e2="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e2" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.p0" relation="true"/>
    <pair e1="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e0" e2="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e3" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.p1" relation="true"/>
    <pair e1="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e1" e2="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e2" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.p2" relation="true"/>
    <pair e1="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e1" e2="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.e3" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c1.p3" relation="true"/>
  </chunk>
  <chunk id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c2" text="Plasmids encoding core with no translation initiation signal (pCMVcore); with Kozak sequence (pCMVcoreKozak); and with HCV IRES (pCMVcoreIRES) were designed and expressed in a variety of eukaryotic cells. Polyproteins corresponding to HCV 1b amino acids (aa) 1-98 and 1-173 were expressed in E. coli. C57BL/6 mice were immunized with four 25-g doses of pCMVcoreKozak, or pCMV (I). BALB/c mice were immunized with 100 g of either pCMVcore, or pCMVcoreKozak, or pCMVcoreIRES, or empty pCMV (II). Lastly, BALB/c mice were immunized with 20 g of core aa 1-98 in prime and boost, or with 100 g of pCMVcoreKozak in prime and 20 g of core aa 1-98 in boost (III). Antibody response, [ 3 H]-T-incorporation, and cytokine secretion by core/core peptide-stimulated splenocytes were assessed after each immunization.">
    <entity charOffset="242-247" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c2.e0" ontology_id="CHEBI_46882" text="amino" type="chemical"/>
    <entity charOffset="242-253" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c2.e1" ontology_id="CHEBI_33704" text="amino acids" type="chemical"/>
    <entity charOffset="248-253" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c2.e2" ontology_id="CHEBI_37527" text="acids" type="chemical"/>
    <entity charOffset="378-381" id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c2.e3" ontology_id="CHEBI_16411" text="Iaa" type="chemical"/>
  </chunk>
  <chunk id="9ad61dcfb0a71ebe88c497995cf569eba5e73f8c.c3" text="Results: Plasmids differed in core-expression capacity: mouse fibroblasts transfected with pCMVcore, pCMVcoreIRES and pCMVcoreKozak expressed 0.22 ± 0.18, 0.83 ± 0.5, and 13 ± 5 ng core per cell, respectively. Single immunization with highly expressing pCMVcoreKozak induced specific IFN- and IL-2, and weak antibody response. Single immunization with plasmids directing low levels of core expression induced similar levels of cytokines, strong T-cell proliferation"/>
</document>
